South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to further develop the anti-cancer vaccine. OVM is anticipated to initiate a Phase Ib study for the vaccine in the UK in the near future, while DxVx will launch a study in Asia, encompassing South Korea and China. The vaccine has previously demonstrated positive results in a Phase Ia study.
OVM-200 is a therapeutic vaccine designed to enter the body and eliminate cancer cells. It has the potential to create an immune memory that can recognize and destroy new cancer cells that may arise over time. The vaccine utilizes ROP (Recombinant Overlapping Peptide) technology, which significantly boosts immune response and vaccine efficacy. As a peptide vaccine, OVM-200 offers safety advantages over mRNA and viral particle-based vaccines.- Flcube.com
